Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 85   

Articles published

NVO 47.75 -0.02 (-0.04%)
price chart
Novo, Orexigen Join Race For Obesity Drugs; Arena-Eisai's Belviq And Vivus's ...
Novo Nordisk A/S (ADR) (NVO) received Food and Drug Administration's (FDA) advisory committee's approval on September 11 for its weight-loss therapy Saxenda, which was earlier prescribed as a treatment for diabetes.
Related articles »  
Corporate Updates: KMG Chemicals, Inc. (NYSE:KMG), Novo Nordisk A/S (ADR ...
Novo Nordisk A/S (ADR) (NYSE:NVO) recently updated that the EMDAC (Endocrinologic and Metabolic Drugs Advisory Committee) of the U.S.
Watch List -Novo Nordisk A/S (ADR) (NYSE:NVO), FirstEnergy Corp. (NYSE:FE ...  Techsonian (press release)
Related articles »  
FDA Expected To Approve Two More Weight Loss Drugs
On the same day, the regulator has invited its advisors to come together and discuss Novo Nordisk A/S' (ADR) (NVO) intravenous injection to combat obesity.
Related articles »  
US Pharma Sales Growth Rebounds
Of these, AbbVie Inc. (ABBV), Novo Nordisk A/S ADR (NVO), and Bayer AG ADR (BAYRY) are expected to see their revenues compound at the highest annual growth rates of 9.6%, 8.9%, and 6.1%, respectively, over the next three years starting from August ...
Watch List - Novo Nordisk A/S (ADR) (NYSE:NVO), Cisco Systems, Inc ...
Manhattan, NY- 11 September, 2014 - (Techsonian) - Novo Nordisk A/S (ADR) (NYSE:NVO) engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark.
Related articles »  
Pharma Stocks: What To Look For In The Week Ahead
... Auxilium Pharmaceuticals, Inc. (AUXL) and Clarus Therapeutics, Inc's testosterone drugs. AstraZeneca, Novo Nordisk A/S (ADR) (NVO) and Eli Lilly and Co (LLY) will present at the annual meeting of European Association for the Study of Diabetes (EASD).
Related articles »  
European stocks dip: Nokia Corporation (NYSE:NOK), Novo Nordisk A/S (NVO ...
Shares of Novo Nordisk A/S (ADR) (NYSE:NVO) were 46.41% off 52 week lows as of the latest close and -1.57% below the 52 week high.
Shire's Drug To Put An End To Binge Eating
... to gain approval in 13 years. An FDA Advisory panel also recommended Novo Nordisk A/S (ADR)'s (NVO) obesity therapy last week.
Related articles »  
Arena Down On The Back Of Weigh-Loss Drug Failure
Arena has been unable to deliver on expectations of its weight-loss drug, Belviq. It has also been plagued with concerns of competition from soon-to-be launched weight loss drugs by Novo Nordisk A/S (ADR) (NVO) and Orexigen Therapeutics, Inc. (OREX).
Related articles »  
Big Pharma: $100 Billion In Future Sales Expected
These late-stage drugs are expected to account for $100 billion in sales by 2018, for large pharmaceuticals like GlaxoSmithKline plc (ADR) (GSK), Novo Nordisk A/S (ADR) (NVO), and Sanofi SA (ADR) (SNY), according to Bloomberg Intelligence. Of these ...